Thus, identification of other therapies targeting CML stem cells, as well as development of complementary therapies that target molecular events downstream of BCR-ABL are two major challenges in the treatment of CML. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.